JMT Cochrane, Board member Wellcome and Glaxo; Director of Commercial Affairs for Europe

Interviewee joined the company in 1990, with the remit to "bring it into the 20th century".

The interview comprises a close assessment of the company, of its relationship with WT, the flotation and the merger with Glaxo. Other topics discussed include:

* biography

* differences between UK and US company

* reasons for flotation and preparations for sale of second lot of shares

* the effects of public accountability on the company, budgeting

* AJ Shepperd as chairman

* restructuring of the business, focus of research, commercial interests

* Semprex

* principles behind marketing drugs, establishing where markets are available, pricing

* salaries and staffing

* research: David Barry and Trevor Jones; relationship between UK and USA research functions

* management of research and product development: Zantac [Glaxo product]

* Wellbutrin

* strategic review of company

* markets in Germany and Japan

* relationship between company and WT

* Glaxo's approach to WT and reasons for wishin to takeover WF; process of selecting staff post-merger

* summary of Glaxo

* WF as an employeer/staff morale and attitudes

* John Robb, management and leadership style

2 audiocassettes Tape 35

Copyright was assigned to the Wellcome Trust for all material created or commissioned by the Wellcome Foundation, its successors and associated companies. The copyright in third party material (ie material not created by WF such as letters and publications from external sources, magazine articles, newspaper cuttings etc) is assumed to remain with the creator or his/her heirs. Where third party material exists, this has been noted at item level.

This item needs to be accessed onsite using specialist equipment. Email collections@wellcomecollection.org to request an appointment.